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CARTILAGE DISORDERS
The importance of being sulphated
Mutations within a gene encoding a novel sulphate transporter cause
diastrophic dysplasia. This finding has implications for the management of
the disorder and for understanding the structure and function of cartilage.
A population register has been maintained by the priests
of the Lutheran Church in Finland since the early 1600s,
and in this register are a large number of entries describ-
ing short, handicapped individuals. The disorder to
which the priests were referring has since been termed
diastrophic dysplasia (DTD) after the Greek word mean-
ing 'twisted'. This autosomal recessively inherited con-
dition has a carrier frequency approaching 1 in 30 in
certain regions of Finland, so it is not surprising that the
identification of the DTD gene, reported recently by
Histbacka et al. [1], was covered by all three television
channels and at least six newspapers around the country
(Ilkka Kaitila, personal communication).
DTD is a well-defined member of a heterogeneous
group of disorders, the chondrodysplasias, all of which
result in alterations in the shape and form of the develop-
ing skeleton [2]. The clinical manifestations of DTD
include short-limbed dwarfism, kyphoskoliosis (com-
bined backward and sideways curvature of the spine),
dysplasia of the joints involving dislocations and contrac-
tures, 'hitchhiker' thumbs' (resulting from marked short-
ening of the first metacarpal, which is more proximally
placed than normal), talipes equinus or equinovarus (club
foot) and often deformation of the ear lobes and cleft
palate. The joint changes are progressive in nature, lead-
ing to secondary premature osteoarthritis. Patients are
severely physically handicapped but their intelligence
and sexual development are within the normal range.
Although DTD is rare in world-wide terms, it is the
most common form of chondrodysplasia in the Finnish
population. The high frequency of the DTD gene in
Finland is thought to have arisen as a a result of the
chance inclusion or occurrence of one mutation in the
small founding population, followed by expansion of the
virtually isolated population.
The clinical phenotype of DTD, as well as biochemical
and ultrastructural studies of tissue from affected people,
have not provided any specific clues as to which of the
myriad genes required for the normal development of
cartilage and bone might be at fault in this disorder [3].
The high frequency of the disorder in Finland meant,
however, that identification of the gene causing the dis-
ease by conventional linkage mapping was feasible.
Linkage was analysed using markers spanning the hu-
man genome in, initially, 13 Finnish families that each
had two or three affected siblings (a total of 83 indivi-
duals), and the DTD gene was mapped to a region of
about 30 centiMorgans (cM) on the distal long arm of
chromosome 5 [4]. Finer localization of the mutated
gene in a total of 18 families mapped DTD to a region of
1.6 cM spanned by the two markers ADRB2 and
SPARC, and in the vicinity of CSF1R; the physical dis-
tance from ADRB2 to CSFIR and from CSF1R to
SPARC had been estimated to be 900 and 1500 kilobases
(kb), respectively [5].
The 18 families used for the mapping studies included
nearly all the families in Finland with multiple affected
members, so finer localization of the DTD gene using
standard recombinational mapping did not seem possi-
ble. Furthermore, no obvious candidate genes were
known to map to that region. For most genetic disor-
ders, investigators would now have to face the daunting
task of mapping transcribed sequences within a region of
about 2 400 kb and screening each newly identified gene
for potential disease-causing mutations. But, once again,
the frequency of the DTD gene in the Finnish popu-
lation offered an alternative approach, that of linkage-
disequilibrium mapping.
Linkage-disequilibrium mapping relies on the premise
that among a collection of chromosomes carrying the
same ancestral mutation, genetic markers in the immedi-
ate vicinity of the disease gene should have recombined
least often and should therefore show a distinctive haplo-
type reflecting that of the ancestral chromosome. This
method of mapping offers increased resolution, because it
exploits recombination events occurring over the entire
history of a population - in contrast to conventional
linkage analysis, which is restricted to data on alleles
present in living generations. In addition, linkage-dis-
equilibrium mapping can be applied to families with only
one affected child, whereas conventional linkage map-
ping requires families with many affected members or a
large number of families with a single affected member.
The introduction of the DTD gene into the small found-
ing population of Finland, the main expansion of which
began some 2000 years ago and has reached the present
population of 5 million, offers an ideal setting for link-
age-disequilibrium mapping. The age of the population
has allowed sufficient time for recombination to narrow
the region of disequilibrium, but not so much time that
many new mutations have arisen; and the population
has expanded to a size large enough to allow disease gene
frequencies to be determined.
To localize the DTD gene by linkage-disequilibrium
mapping, haplotypes of members of the original 18
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families, as well as 59 additional Finnish DTD families
having a single affected child (a total of 144 DTD-
bearing chromosomes), were determined for 11 markers
[1,5]. Striking linkage disequilibrium was found between
DTD and two polymorphisms (identified by restriction
enzymes EcoRI and Styl) within CSF1R. The haplotype
(termed the ancestral haplotype) at these two marker loci
was present on 95 % of DTD-bearing chromosomes but
was relatively rare (3 %) on normal chromosomes. This
information was used to estimate the distance between
DTD and CSF1R using the Luria-Delbruck equations
[6]. Assuming that most DTD cases can be traced to a
common ancestor in the main founding Finnish popu-
lation, and that recombination between DTD and
CSF1R removed the ancestral haplotype, then the 5 % of
DTD chromosomes having haplotypes other than the
ancestral one must have arisen through recombination.
This level of recombination occurring over 100 genera-
tions would correspond to a recombination distance of
0.06 cM. Assuming the average correspondence of 1 cM
to 1 megabase of the human genome, DTD would be
predicted to lie within about 60 kb of CSF1R.
Detailed analysis of other polymorphic markers and the
recombination events that had occurred, within the
ancestral haplotype placed DTD at a locus proximal to
CSF1R [1]. Attempts to identify the DTD gene within
the predicted 60 kb region followed rapidly. The region
was spanned by a genomic clone and the sequence of
the centromeric end of this clone was found to be
homologous to a rat gene, sat-i, encoding a sulphate
transporter. The subclone was used to probe RNA
extracted from a series of tissues, including fibroblasts,
and hybridized to a messenger (m)RNA of 8.4 kb. This
mRNA was not present in RNA isolated from fibro-
blasts derived from two Finnish DTD patients, strongly
suggesting that the 8.4 kb mRNA was derived from
the DTD gene.
The corresponding gene was cloned and sequenced and
found to encode a protein of 739 amino acids. Using
sequence comparisons, the gene was predicted to
encode a novel sulphate transporter containing 12 trans-
membrane helices with highly charged cytoplasmic
domains at both the amino and carboxyl termini. Pre-
liminary analysis of sulphate transporter activity in fibro-
blasts from a single Finnish patient demonstrated
diminished sulphate uptake. Confirmation that the DTD
gene had indeed been identified came from analysis of
2.4 kb of the 8.4 kb transcript and the identification of
three mutations likely to have a major effect - two
frame-shift mutations which would lead to premature
termination and truncation of the protein, and a splicing
mutation - in genomic DNA from five non-Finnish
patients. The individuals were all heterozygous for the
mutations detected and presumably carried a different
DTD mutation on their other DTD allele. As yet, the
common Finnish mutation has not been detected, but
this is not surprising as only 30 % of the coding
sequence has been examined to date.
The tissue-specific manifestation of the DTD phenotype
is difficult to explain as the result of aberrant sulphate
transporter activity in the light of available data. It is
possible, however, to hypothesize what effects decreased
intracellular sulphate levels might have on aspects of car-
tilage structure and function that would explain some of
the specific changes in the extracellular matrix and cellu-
lar component of DTD growth cartilage [3]. Cartilage
consists of two major classes of macromolecules, proteo-
glycans and collagens [7]. Proteoglycans are glycoproteins
in which one or more sulphated polysaccharide chains,
the glycosaminoglycans (GAGs), are covalently linked to
the protein. The highly acidic and hydrophilic GAGs
have a major influence on tissue hydration, elasticity and
cation composition, and they participate directly in high-
affinity binding to extracellular matrix proteins, growth
factors, enzymes and cell surface receptors.
The proteoglycan aggrecan is one of the major structural
components of cartilage. It contains a core protein that is
extensively modified by substitution with the GAG side-
chains chondroitin sulphate and keratin sulphate, and
many of these modified molecules bind to hyaluronic
acid to form large aggregates (Fig. 1). Undersulphation
or absence of the GAG side-chains, such as might occur
if cellular sulphate transport were deficient, is likely to
affect the function of aggrecan drastically. The impor-
tance of aggrecan in terms of cartilage structure and
function has been demonstrated by the finding that a
mutation in the encoding gene causes an autosomal
recessive lethal disease of the mouse, cartilage matrix
deficiency, which is characterized by disproportionate
dwarfism, short snout and cleft palate [8].
Fig. 1. Schematic representation of aggrecan with hyaluronate
and link protein. The central core protein with three globular
domains (G1, G2 and G3) is substituted with a large number of
negatively charged GAG chains, either keratin sulphate or chon-
droitin sulphate. Many aggrecan moieties attach to hyaluronate




cell-surface tyrosine kinase receptors that recognize a
particular conformation of bFGF that is induced by its
binding to cell surface heparan sulphate (Fig. 2) [9]. It is
possible that undersulphation of heparan sulphate in
DTD might influence its role in the transfer of bFGF
and other growth factors to specific high-affinity recep-
tors. Interestingly, mutations in the gene encoding the
FGF receptor 3 have been found to cause the most com-
mon form of chondrodysplasia in man, achondroplasia,
which is characterized by short-limbed dwarfism and
macrocephaly [10].
The finding that the basic defect underlying DTD is a
mutation in a sulphate transporter gene has raised some
interesting conundrums that demand targeted studies
aimed at tracing the pathway between mutation and
phenotype. For the individuals with the disorder and
their families, the possibilities of accurate carrier detec-
tion and prenatal diagnosis are now in sight, although
therapeutic advances may have to wait a little longer.
Fig. 2. Proposed mechanism of bFGF activation by heparin sul-
phate. The bFGF is inactive unless it binds to cell surface heparin
sulphate, which induces a conformational change rendering the
bFGF active and able to engage the signal-transducing receptors.
Adapted from [11].
The second main component of cartilage is collagen.
The collagen fibril network of cartilage consists primarily
of type II collagen; collagen type IX and type XI are
minor components and are covalently bound to type II
collagen. Type XI collagen forms the core of the type II
fibrils, whereas type IX is found on the surface of the
type II collagen fibrils and may play a role in the inter-
action of the fibrillar network with other molecules, and
in the regulation of type II collagen fibrillar assembly.
Type IX collagen, in cartilaginous and vitreous tissues,
is frequently substituted with a GAG side-chain (pre-
dominantly chondroitin sulphate). Undersulphation or
absence of the GAG chain could potentially alter the spe-
cific function of type IX collagen in these tissues, again
suggesting a defect that might arise as a result of sulphate
transport deficiency.
Apart from the function of proteoglycans in the matrix
of cartilage, certain proteoglycans, such as heparan sul-
phate, are known to be associated with cell-surface
membranes and to influence various fundamental aspects
of cell behaviour such as adhesion, growth, and morpho-
genesis. For example, heparan sulphate proteoglycans of
the plasma membrane have a role in regulating the activ-
ity of basic fibroblast growth factor (bFGF); bFGF elicits
responses in cells by binding to specific high-affinity
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